公开(公告)号：US20220257631A1

公开(公告)日：2022-08-18

申请号：US17595587

申请日：2020-05-20

Applicant: BIONTECH SE ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ

Inventor： Ugur SAHIN ,  David WEBER ,  Carina WALTER ,  Diana BAREA ROLDAN ,  Ruprecht KUNER ,  Meike WAGNER ,  Martin SUCHAN ,  Stefania GANGI MAURICI ,  Stefanie HUBICH-RAU ,  René BECKER

IPC: A61K31/7088 ,  A61P35/00 ,  A61K9/00

Abstract: Disclosed herein are compositions, uses, and methods for treatment of ovarian cancers. In one aspect, provided herein is a composition or medical preparation comprising at least one RNA, wherein the at least one RNA encodes the following amino acid sequences: (i) an amino acid sequence comprising claudin 6 (CLDN6), an immunogenic variant thereof, or an immunogenic fragment of the CLDN6 or the immunogenic variant thereof; (ii) an amino acid sequence comprising p53, an immunogenic variant thereof, or an immunogenic fragment of the p53 or the immunogenic variant thereof; and (iii) an amino acid sequence comprising Preferentially Expressed Antigen In Melanoma (PRAME), an immunogenic variant thereof, or an immunogenic fragment of the PRAME or the immunogenic variant thereof.

公开(公告)号：US20240263232A1

公开(公告)日：2024-08-08

申请号：US18420361

申请日：2024-01-23

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Martin SUCHAN ,  Barbara SCHRÖRS ,  Martin LÖWER ,  Petra OEHM

IPC: C12Q1/6876 ,  C12Q1/686

CPC classification number: C12Q1/6876 ,  C12Q1/686 ,  C12Q2600/156

Abstract: This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.

公开(公告)号：US20230114808A1

公开(公告)日：2023-04-13

申请号：US17310773

申请日：2020-03-11

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Gemein-N

Inventor： David WEBER ,  Carina WALTER ,  Diana BAREA ROLDAN ,  Ruprecht KUNER ,  Elif DIKEN ,  Martin SUCHAN ,  Stefania GANGI MAURICI ,  Ugur SAHIN

IPC: A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  A61K45/06 ,  A61K39/395 ,  A61K39/39

Abstract: Disclosed herein are compositions, uses, and methods for treatment of prostate cancers. In one aspect, disclosed herein is a composition or medical preparation comprising at least one RNA, wherein the at least one RNA encodes the following amino acid sequences: (i) an amino acid sequence comprising Kallikrein-2 (KLK2), an immunogenic variant thereof, or an immunogenic fragment of the KLK2 or the immunogenic variant thereof; (ii) an amino acid sequence comprising Prostate Specific Antigen (PSA), an immunogenic variant thereof, or an immunogenic fragment of the PSA or the immunogenic variant thereof; (iii) an amino acid sequence comprising Prostatic Acid Phosphatase (PAP), an immunogenic variant thereof, or an immunogenic fragment of the PAP or the immunogenic variant thereof; (iv) an amino acid sequence comprising Homeobox B13 (HOXB13), an immunogenic variant thereof, or an immunogenic fragment of the HOXB13 or the immunogenic variant thereof; and (v) an amino acid sequence comprising NK3 Homeobox 1 (NKX3-1), an immunogenic variant thereof, or an immunogenic fragment of the NKX3-1 or the immunogenic variant thereof.